Normal human and rat sera enhanced the in vitro activity of thiamphenicol (TAPH) and chloramphenicol (CAPH) on 8 strains of gram-negative bacteria, TAPH being activated much more than CAPH with respect to the bactenostatic activity, and CAPH little more than TAPH as regards the bactericidal activity. The effect of serum on the TAPH and CAPH activity against 5 gram-positive strains was in most cases null or (principally for CAPH) even depressing. As a whole, TAPH was either activated more than CAPH (principally as regards the bacteriostatic activity) or less antagonized than it (against the gram-positive strains) by serum; this may account for the frequent in vivo increase of the activity of TAPH up to equal or even superior levels as compared to CAPH, despite its lower in vitro activity.

The primary immune response consisting of humoral antibody production to sheep red blood cells and Proteus X₁₉O antigen injected intravenously was considerably inhibited in rabbits by a thiamphenicol (TAPH) treatment (i.m., 100 mg/kg daily for 12 days) initiated 8 h before the antigen injection. A similar course of chloramphenicol (CAPH) treatment had no immunosuppressive effect, due probably to the higher inactivation rate of CAPH in the rabbit. The immunosuppressive effect of TAPH lasted only as long as the treatment period. Antibody titers in TAPH-treated animals increased to lower values, with respect to controls during this period, after which, instead, the rate of antibody production in the treated rabbits became higher than in the controls, so that 48 h after the last TAPH injection no significant differences between the titers of the two groups were noted any more. The secondary immune response to the same antigens was not influenced, neither in the rabbits treated with TAPH during the primary response, nor in others which received CAPH during the primary immunization and were treated with TAPH during the secondary immunization. Discussing these findings in connection with literature data, it is concluded that TAPH inhibits the immune response by impeding the proliferation of the antigen-stimulated cells rather than by impairing the actual process of immunoglobulin synthesis.

Heart failure is still the leading cause of hospitalization in patients over 65 years of age and is defined as a multifactorial pathology which involves environmental factors and also genetic predispositions. The aim of the present study was to evaluate a possible correlation between single nucleotide polymorphisms (SNPs) of angiotensin converting enzyme 2 (ACE2) and monocyte chemoattractant protein-1 (MCP-1) genes and cardiac remodeling in Caucasian patients diagnosed with heart failure. Our comparative translational research study included 116 patients diagnosed with heart failure and was carried out in Cluj-Napoca, Romania between September 2017 and March 2019. Three SNPs, namely rs4646156, rs4646174 and rs1024611, were genotyped using a Taqman real-time PCR technique. Our results showed that carriers of the AA genotype for ACE2 rs4646156 had a significant dilatation of the left ventricle (LV) with signs of LV hypertrophy (LVH), while TT carriers had a significant left atrial dilatation. For ACE2 rs4646174, homozygotes for the C allele presented a dilated LV with signs of LVH with statistical significance and had a tendency towards a lower ejection fraction. MCP-1 rs1024611 AA variant carriers had a significant LVH in the dominant model. In conclusion, our study showed a strong association between echocardiographic parameters of cardiac remodeling and SNPs rs4646156, rs4646174 of ACE2 and rs1024611 of MCP-1.

Of 30 patients with severe, complicated U.T.I. 27 have been given single daily doses of Kelfiprim (KP), a new sulfatrimethoprim combination, for 8 weeks. In 24 bacteriuria was lastingly controlled, one had a relapse, one had a reinfection, and in one, with bladder carcinoma, bacteriuria persisted. Three other patients received KP for shorter periods, as they presented gastric intolerance or skin hypersensitivity, but in two of them a lasting sterilization of the urine has been obtained. The usefulness of a single daily dose schedule is stressed.

No abstract